Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina : A randomized, double-blind, placebo-controlled study
Experimental studies suggest that androgens induce coronary vasodilatation. We performed this pilot project to examine the clinical effects of long-term low-dose androgens in men with angina. Forty-six men with stable angina completed a 2-week, single-blind placebo run-in, followed by double-blind r...
Gespeichert in:
| Veröffentlicht in: | Circulation (New York, N.Y.) N.Y.), 2000-10, Vol.102 (16), p.1906-1911 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1911 |
|---|---|
| container_issue | 16 |
| container_start_page | 1906 |
| container_title | Circulation (New York, N.Y.) |
| container_volume | 102 |
| creator | ENGLISH, Katherine M STEEDS, Richard P JONES, T. Hugh DIVER, Michael J CHANNER, Kevin S |
| description | Experimental studies suggest that androgens induce coronary vasodilatation. We performed this pilot project to examine the clinical effects of long-term low-dose androgens in men with angina.
Forty-six men with stable angina completed a 2-week, single-blind placebo run-in, followed by double-blind randomization to 5 mg testosterone daily by transdermal patch or matching placebo for 12 weeks, in addition to their current medication. Time to 1-mm ST-segment depression on treadmill exercise testing and hormone levels were measured and quality of life was assessed by SF-36 at baseline and after 4 and 12 weeks of treatment. Active treatment resulted in a 2-fold increase in androgen levels and an increase in time to 1-mm ST-segment depression from (mean+/-SEM) 309+/-27 seconds at baseline to 343+/-26 seconds after 4 weeks and to 361+/-22 seconds after 12 weeks. This change was statistically significant compared with that seen in the placebo group (from 266+/-25 seconds at baseline to 284+/-23 seconds after 4 weeks and to 292+/-24 seconds after 12 weeks; P:=0.02 between the 2 groups by ANCOVA). The magnitude of the response was greater in those with lower baseline levels of bioavailable testosterone (r=-0. 455, P: |
| doi_str_mv | 10.1161/01.CIR.102.16.1906 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_212755973</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66263442</sourcerecordid><originalsourceid>FETCH-LOGICAL-c281t-d2997892f5ff2c3836aaff7d2525a126877d57d75e2df81f563de9bb5363b62d3</originalsourceid><addsrcrecordid>eNpFkc2OFCEUhYnROO3oC7gwxLi0Si40UOVu0vFnkk5MjK4JxY_NhIIWqmbSPosPK5NpMytyuN855HIQeg2kBxDwgUC_u_7eA6E9iB5GIp6gDXC67bacjU_RhhAydpJReoFe1HrTpGCSP0cXAIRtRyY36O8-33U2V4eXolO1rsw64sXVJdfFlZza4OCKPp5wmI8l37qKdfoVkm73xdVDjhaHhGeX8F1YDtgcmikYXBc9Rfef_YivcMu3eQ5_nH2PbV7btJtiSE0dozZuyp3JaSk5RmebfbWnl-iZ17G6V-fzEv38_OnH7mu3__blene17wwdYOksHUc5jNRz76lhAxNaey8t5ZRroGKQ0nJpJXfU-gE8F8y6cZo4E2wS1LJL9PYhty34e227q5u8ltSeVBSo5HyUrEH0ATIl11qcV8cSZl1OCoi670MRUK2PJqkCoe77aKY35-R1mp19tJwLaMC7M6Cr0dG3TzKhPnKcAVBg_wAwnZWv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212755973</pqid></control><display><type>article</type><title>Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina : A randomized, double-blind, placebo-controlled study</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>ENGLISH, Katherine M ; STEEDS, Richard P ; JONES, T. Hugh ; DIVER, Michael J ; CHANNER, Kevin S</creator><creatorcontrib>ENGLISH, Katherine M ; STEEDS, Richard P ; JONES, T. Hugh ; DIVER, Michael J ; CHANNER, Kevin S</creatorcontrib><description>Experimental studies suggest that androgens induce coronary vasodilatation. We performed this pilot project to examine the clinical effects of long-term low-dose androgens in men with angina.
Forty-six men with stable angina completed a 2-week, single-blind placebo run-in, followed by double-blind randomization to 5 mg testosterone daily by transdermal patch or matching placebo for 12 weeks, in addition to their current medication. Time to 1-mm ST-segment depression on treadmill exercise testing and hormone levels were measured and quality of life was assessed by SF-36 at baseline and after 4 and 12 weeks of treatment. Active treatment resulted in a 2-fold increase in androgen levels and an increase in time to 1-mm ST-segment depression from (mean+/-SEM) 309+/-27 seconds at baseline to 343+/-26 seconds after 4 weeks and to 361+/-22 seconds after 12 weeks. This change was statistically significant compared with that seen in the placebo group (from 266+/-25 seconds at baseline to 284+/-23 seconds after 4 weeks and to 292+/-24 seconds after 12 weeks; P:=0.02 between the 2 groups by ANCOVA). The magnitude of the response was greater in those with lower baseline levels of bioavailable testosterone (r=-0. 455, P:<0.05). There were no significant changes in prostate specific antigen, hemoglobin, lipids, or coagulation profiles during the study. There were significant improvements in pain perception (P:=0.026) and role limitation resulting from physical problems (P:=0.024) in the testosterone-treated group.
Low-dose supplemental testosterone treatment in men with chronic stable angina reduces exercise-induced myocardial ischemia.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/01.CIR.102.16.1906</identifier><identifier>PMID: 11034937</identifier><identifier>CODEN: CIRCAZ</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Administration, Cutaneous ; Analysis of Variance ; Angina Pectoris - drug therapy ; Biological and medical sciences ; Cardiology. Vascular system ; Chronic Disease ; Coronary heart disease ; Dose-Response Relationship, Drug ; Double-Blind Method ; Exercise Test - drug effects ; Gonadal Steroid Hormones - administration & dosage ; Gonadal Steroid Hormones - adverse effects ; Heart ; Humans ; Male ; Medical sciences ; Middle Aged ; Pain Threshold - drug effects ; Pilot Projects ; Quality of Life ; Testosterone - administration & dosage ; Testosterone - adverse effects ; Treatment Outcome</subject><ispartof>Circulation (New York, N.Y.), 2000-10, Vol.102 (16), p.1906-1911</ispartof><rights>2000 INIST-CNRS</rights><rights>Copyright American Heart Association, Inc. Oct 17, 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c281t-d2997892f5ff2c3836aaff7d2525a126877d57d75e2df81f563de9bb5363b62d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3674,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1531121$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11034937$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ENGLISH, Katherine M</creatorcontrib><creatorcontrib>STEEDS, Richard P</creatorcontrib><creatorcontrib>JONES, T. Hugh</creatorcontrib><creatorcontrib>DIVER, Michael J</creatorcontrib><creatorcontrib>CHANNER, Kevin S</creatorcontrib><title>Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina : A randomized, double-blind, placebo-controlled study</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>Experimental studies suggest that androgens induce coronary vasodilatation. We performed this pilot project to examine the clinical effects of long-term low-dose androgens in men with angina.
Forty-six men with stable angina completed a 2-week, single-blind placebo run-in, followed by double-blind randomization to 5 mg testosterone daily by transdermal patch or matching placebo for 12 weeks, in addition to their current medication. Time to 1-mm ST-segment depression on treadmill exercise testing and hormone levels were measured and quality of life was assessed by SF-36 at baseline and after 4 and 12 weeks of treatment. Active treatment resulted in a 2-fold increase in androgen levels and an increase in time to 1-mm ST-segment depression from (mean+/-SEM) 309+/-27 seconds at baseline to 343+/-26 seconds after 4 weeks and to 361+/-22 seconds after 12 weeks. This change was statistically significant compared with that seen in the placebo group (from 266+/-25 seconds at baseline to 284+/-23 seconds after 4 weeks and to 292+/-24 seconds after 12 weeks; P:=0.02 between the 2 groups by ANCOVA). The magnitude of the response was greater in those with lower baseline levels of bioavailable testosterone (r=-0. 455, P:<0.05). There were no significant changes in prostate specific antigen, hemoglobin, lipids, or coagulation profiles during the study. There were significant improvements in pain perception (P:=0.026) and role limitation resulting from physical problems (P:=0.024) in the testosterone-treated group.
Low-dose supplemental testosterone treatment in men with chronic stable angina reduces exercise-induced myocardial ischemia.</description><subject>Administration, Cutaneous</subject><subject>Analysis of Variance</subject><subject>Angina Pectoris - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Chronic Disease</subject><subject>Coronary heart disease</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Exercise Test - drug effects</subject><subject>Gonadal Steroid Hormones - administration & dosage</subject><subject>Gonadal Steroid Hormones - adverse effects</subject><subject>Heart</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pain Threshold - drug effects</subject><subject>Pilot Projects</subject><subject>Quality of Life</subject><subject>Testosterone - administration & dosage</subject><subject>Testosterone - adverse effects</subject><subject>Treatment Outcome</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkc2OFCEUhYnROO3oC7gwxLi0Si40UOVu0vFnkk5MjK4JxY_NhIIWqmbSPosPK5NpMytyuN855HIQeg2kBxDwgUC_u_7eA6E9iB5GIp6gDXC67bacjU_RhhAydpJReoFe1HrTpGCSP0cXAIRtRyY36O8-33U2V4eXolO1rsw64sXVJdfFlZza4OCKPp5wmI8l37qKdfoVkm73xdVDjhaHhGeX8F1YDtgcmikYXBc9Rfef_YivcMu3eQ5_nH2PbV7btJtiSE0dozZuyp3JaSk5RmebfbWnl-iZ17G6V-fzEv38_OnH7mu3__blene17wwdYOksHUc5jNRz76lhAxNaey8t5ZRroGKQ0nJpJXfU-gE8F8y6cZo4E2wS1LJL9PYhty34e227q5u8ltSeVBSo5HyUrEH0ATIl11qcV8cSZl1OCoi670MRUK2PJqkCoe77aKY35-R1mp19tJwLaMC7M6Cr0dG3TzKhPnKcAVBg_wAwnZWv</recordid><startdate>20001017</startdate><enddate>20001017</enddate><creator>ENGLISH, Katherine M</creator><creator>STEEDS, Richard P</creator><creator>JONES, T. Hugh</creator><creator>DIVER, Michael J</creator><creator>CHANNER, Kevin S</creator><general>Lippincott Williams & Wilkins</general><general>American Heart Association, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>U9A</scope></search><sort><creationdate>20001017</creationdate><title>Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina : A randomized, double-blind, placebo-controlled study</title><author>ENGLISH, Katherine M ; STEEDS, Richard P ; JONES, T. Hugh ; DIVER, Michael J ; CHANNER, Kevin S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c281t-d2997892f5ff2c3836aaff7d2525a126877d57d75e2df81f563de9bb5363b62d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Administration, Cutaneous</topic><topic>Analysis of Variance</topic><topic>Angina Pectoris - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Chronic Disease</topic><topic>Coronary heart disease</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Exercise Test - drug effects</topic><topic>Gonadal Steroid Hormones - administration & dosage</topic><topic>Gonadal Steroid Hormones - adverse effects</topic><topic>Heart</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pain Threshold - drug effects</topic><topic>Pilot Projects</topic><topic>Quality of Life</topic><topic>Testosterone - administration & dosage</topic><topic>Testosterone - adverse effects</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ENGLISH, Katherine M</creatorcontrib><creatorcontrib>STEEDS, Richard P</creatorcontrib><creatorcontrib>JONES, T. Hugh</creatorcontrib><creatorcontrib>DIVER, Michael J</creatorcontrib><creatorcontrib>CHANNER, Kevin S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ENGLISH, Katherine M</au><au>STEEDS, Richard P</au><au>JONES, T. Hugh</au><au>DIVER, Michael J</au><au>CHANNER, Kevin S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina : A randomized, double-blind, placebo-controlled study</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>2000-10-17</date><risdate>2000</risdate><volume>102</volume><issue>16</issue><spage>1906</spage><epage>1911</epage><pages>1906-1911</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><coden>CIRCAZ</coden><abstract>Experimental studies suggest that androgens induce coronary vasodilatation. We performed this pilot project to examine the clinical effects of long-term low-dose androgens in men with angina.
Forty-six men with stable angina completed a 2-week, single-blind placebo run-in, followed by double-blind randomization to 5 mg testosterone daily by transdermal patch or matching placebo for 12 weeks, in addition to their current medication. Time to 1-mm ST-segment depression on treadmill exercise testing and hormone levels were measured and quality of life was assessed by SF-36 at baseline and after 4 and 12 weeks of treatment. Active treatment resulted in a 2-fold increase in androgen levels and an increase in time to 1-mm ST-segment depression from (mean+/-SEM) 309+/-27 seconds at baseline to 343+/-26 seconds after 4 weeks and to 361+/-22 seconds after 12 weeks. This change was statistically significant compared with that seen in the placebo group (from 266+/-25 seconds at baseline to 284+/-23 seconds after 4 weeks and to 292+/-24 seconds after 12 weeks; P:=0.02 between the 2 groups by ANCOVA). The magnitude of the response was greater in those with lower baseline levels of bioavailable testosterone (r=-0. 455, P:<0.05). There were no significant changes in prostate specific antigen, hemoglobin, lipids, or coagulation profiles during the study. There were significant improvements in pain perception (P:=0.026) and role limitation resulting from physical problems (P:=0.024) in the testosterone-treated group.
Low-dose supplemental testosterone treatment in men with chronic stable angina reduces exercise-induced myocardial ischemia.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>11034937</pmid><doi>10.1161/01.CIR.102.16.1906</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-7322 |
| ispartof | Circulation (New York, N.Y.), 2000-10, Vol.102 (16), p.1906-1911 |
| issn | 0009-7322 1524-4539 |
| language | eng |
| recordid | cdi_proquest_journals_212755973 |
| source | MEDLINE; American Heart Association Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete |
| subjects | Administration, Cutaneous Analysis of Variance Angina Pectoris - drug therapy Biological and medical sciences Cardiology. Vascular system Chronic Disease Coronary heart disease Dose-Response Relationship, Drug Double-Blind Method Exercise Test - drug effects Gonadal Steroid Hormones - administration & dosage Gonadal Steroid Hormones - adverse effects Heart Humans Male Medical sciences Middle Aged Pain Threshold - drug effects Pilot Projects Quality of Life Testosterone - administration & dosage Testosterone - adverse effects Treatment Outcome |
| title | Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina : A randomized, double-blind, placebo-controlled study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T18%3A19%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low-dose%20transdermal%20testosterone%20therapy%20improves%20angina%20threshold%20in%20men%20with%20chronic%20stable%20angina%20:%20A%20randomized,%20double-blind,%20placebo-controlled%20study&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=ENGLISH,%20Katherine%20M&rft.date=2000-10-17&rft.volume=102&rft.issue=16&rft.spage=1906&rft.epage=1911&rft.pages=1906-1911&rft.issn=0009-7322&rft.eissn=1524-4539&rft.coden=CIRCAZ&rft_id=info:doi/10.1161/01.CIR.102.16.1906&rft_dat=%3Cproquest_cross%3E66263442%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212755973&rft_id=info:pmid/11034937&rfr_iscdi=true |